Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.
In adults with metastatic NSCLC controlled after 6 months of first-line nivolumab plus ipilimumab, this prematurely interrupted randomized phase III trial reported no apparent four-year survival harm from stopping treatment, alongside fewer severe treatment-related adverse events and delayed quality-of-life deterioration versus continuation.
Open original publication →What the AI sees
In adults with metastatic NSCLC controlled after 6 months of first-line nivolumab plus ipilimumab, this prematurely interrupted randomized phase III trial reported no apparent four-year survival harm from stopping treatment, alongside fewer severe treatment-related adverse events and delayed quality-of-life deterioration versus continuation.
Research significance
The trial provides direct adult evidence that fixed-duration nivolumab–ipilimumab may reduce toxicity and quality-of-life burden without an evident survival penalty in selected patients with controlled NSCLC; whether response-adapted immunotherapy de-escalation could benefit pediatric or adolescent cancers is an untested inference.
Source abstract
INTRODUCTION: Optimal first-line immunotherapy duration in metastatic NSCLC with controlled disease remains unclear. We evaluated 6-month nivolumab-ipilimumab (Nivo-Ipi) in patients with disease control (DC). METHODS: This randomized, open-label, noninferiority trial enrolled treatment-naive patients with metastatic NSCLC (aged 18-75 y, Eastern Cooperative Oncology Group performance status 0-1, no actionable genomic alterations). After 6-month induction treatment with Nivo (3 mg/kg biweekly) plus Ipi (1 mg/kg every 6 wk), patients with DC were randomized to continue treatment or stop and resume at disease progression. The primary outcome was progression-free survival (PFS). RESULTS: Among 265 patients enrolled, 71 were randomized to the continuation control arm (n = 36) or to the experimental arm (n = 35), with trial premature interruption because of the lack of European filing for the immunotherapy combination. Median PFS follow-up was 47.8 months (95% confidence interval [CI]: 43.1-51.0). In the per-protocol population, median PFS was 18.7 months (95% CI: 7.1-37.1) in the continuation arm versus not reached (NR) (95% CI: 16.1-NR) in the experimental arm. Median OS was 55.5 months (95% CI: 32.4-NR) in the continuation arm versus NR in the experimental group. The 18-month OS was 80.6% (95% CI: 63.5-90.2) and 93.8% (95% CI: 77.3-98.4), respectively. Grade 3 to 5 treatment-related adverse event rates were higher in the continuation arm (54.3% versus 23.5%). Median time until definitive quality-of-life deterioration was 15.5 months (95% CI: 10.0-NR) for the continuation arm but NR in the experimental arm (hazard ratio = 0.36, 95% CI: 0.14-0.92, p = 0.03). CONCLUSIONS: Stopping Nivo-Ipi combination at 6 months in DC patients demonstrated no survival harm at 4 years, reduced severe immune-related adverse events, and delayed quality-of-life deterioration.